三种乳腺癌化疗方案的药物经济学分析

徐素梅; 吕淑河; 王雨露; 李岱; 徐平声<sup>*</sup>

引用本文:	徐素梅,吕淑河,王雨露,李岱,徐平声.三种乳腺癌化疗方案的药物经济学分析[J].中国现代应用药学,2018,35(2):271-274.
	XU Sumei,LYU Shuhe,WANG Yulu,LI Dai,XU Pingsheng.Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(2):271-274.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2779次下载 3569次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
三种乳腺癌化疗方案的药物经济学分析
徐素梅¹, 吕淑河², 王雨露¹, 李岱¹, 徐平声¹
1.中南大学湘雅医院国家药物临床试验机构, 长沙 410008;2.中南大学湘雅医院药学部, 长沙 410008

摘要:

目的从药物经济学角度评价乳腺癌术后3种化疗方案的经济学效果，为临床合理用药提供参考。方法 90例乳腺癌术后患者分为3组[TAC组（多西他赛+多柔比星+环磷酰胺）、PEC组（紫杉醇脂质体+表柔比星+环磷酰胺）、AC组（多柔比星+环磷酰胺）]，采用药物经济学的成本-效果分析法对3种化疗方案进行临床病例的回顾性分析比较。结果 3组化疗方案的总体有效率分别为71.87%，73.07%，65.62%；治疗成本分别为11 713.49元，18 197.79元和7 795.82元；成本-效果比分别为162.98，249.04，118.80。化疗不良反应方面，PEC组发生率高于TAC组及AC组。结论 TAC为乳腺癌术后化疗较佳的治疗方案，值得推广。

关键词: 成本-效果药物经济学乳腺癌敏感度分析

DOI：10.13748/j.cnki.issn1007-7693.2018.02.026

分类号:R969.3

基金项目:

Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer

XU Sumei¹, LYU Shuhe², WANG Yulu¹, LI Dai¹, XU Pingsheng¹

1.National Institution of Drug Clinical Trail, Xiangya Hospital Central South University, Changsha 410008, China;2.Department of Pharmacy, Xiangya Hospital Central South University, Changsha 410008, China

Abstract:

OBJECTIVE To evaluate the cost-effectiveness of three chemotherapy schemes in postoperative treatment of mammary cancer, providing a basis for the further drug administration. METHODS Ninety postoperative patients with mammary cancer were divided into three groups[TAC group (docetaxel + doxorubicin + cyclophosphamide), PEC group (paclitaxel + epirubicin + cyclophosphamide), and AC group (doxorubicin + cyclophosphamide)], the cost-effectiveness method in pharmacoeconomics was adopted to analyze retrospectively the three different regimens.RESULTS The overall response rate for TAC, PEC and AC were 71.87%, 73.07% and 65.62%, respectively; the costs were 11 713.49, 18 197.79 and 7 795.82 yuan, respectively, with corresponding cost-effectiveness ratios of 162.98, 249.04 and 118.80. For the chemotherapy toxicity, the PEC group was higher than those of the TAC group and AC group. CONCLUSION Scheme TAC is a better approach for postoperative treatment of soaked mammary cancer.

Key words: cost-effectiveness analysis pharmacoeconomics mammary cancer sensitivity analysis